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Randomized trials have played a fundamental role in identifying better treatments for
most type of diseases, especially in the oncological field. In breast cancer, the shift
from “maximum tolerable” to “minimum effective” treatment has been evident since the
1970s and has been based on the results of international randomized trials. The progress
of breast surgery represents an excellent model of the evolution of science and the aim
of this article is to review the main randomized studies that changed everyday practice in
breast surgery.
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Medical science has gone through an important evolution in
the past century that was based on the progress in research and
on the advances in technology. The field of surgical oncology is
important, as surgery represents the most common and essential
treatment for solid tumors. In the last 50 years a lot of effort was
made to improve the treatment modalities, in order not only to
prolong the survival, but also to ensure a good quality of life. The
advances achieved are greatly attributed to the clinical research.
The aim of clinical research is the collection of evidence in order
to establish the best treatment and this is achieved through clini-
cal trials. They may be observational studies, when the results of a
treatment procedure are compared with the historical controls.
Randomized trials are the most valid and the most commonly
used in surgical oncology, as they give information regarding the
efficacy of a new procedure by comparing homogeneous groups
of patients who undergo different treatments.
The first randomized trial was published in 1948 in British
Medical Journal and reported on the effects of streptomycin on
pulmonary tuberculosis (1948). Throughout the years this type
of clinical trial was established as the gold standard of evidence
based medicine. In 1996, the guidelines for reporting random-
ized trials were published for the first time and were updated in
2010 (Altman, 1996; Schulz et al., 2010). Simple Randomization,
similar to “fair coin-tossing,” was the most commonly used in
the early periods mainly for trials with up to 200 participants
(Schulz and Grimes, 2002). Today, for larger trials, the restricted
randomization is preferred, in order to guarantee group sizes
balance. Another important parameter is the allocation con-
cealment. According to this procedure, the participant and the
researcher are not aware of the treatment allocation, until after
the patient enters the study, thus ensuring complete impartial-
ity. Possible disadvantages of a randomized trial are high cost,
long duration, and limited external validity, as the results can-
not always be widely applied outside the participating centers.
From the ethical point of view, an informed consent signed by the
participant is mandatory, as well as the approval of the study by
the hospital ethics committee. Every participant has to be thor-
oughly informed about the possible treatments, he will or will
not receive, and about their possible side effects and implications.
The task of ethics committee or the institutional review board
(IRB) is to approve or disapprove, and to monitor the course
of the trial bearing into consideration the rights of the par-
ticipants. When all the necessary criteria are met, the analysis
of the data provided by a randomized trial gives evidence on
Therapy/Prevention and Harm according to the Oxford Centre
for Evidence-based Medicine (2010).
FROM HALSTED MASTECTOMY TO BREAST CONSERVATION
Randomized trials have played a fundamental role in identifying
better treatments for most type of diseases, especially in the onco-
logical field. Although, it is statistically easy to compare two
or more treatments, with an expected quantitative difference at
the endpoint -usually the survival-, it is much more difficult to
compare two treatments that are not expected to be quantita-
tively different. This is relevant for studies that aim at evaluating
improvement in quality of life offered by conservative treatments.
In this case no difference in survival is expected, but qualitative
parameters, such as quality of life, which are however, difficult
to be quantified. These trials, named “equivalence trials,” have an
important role to proceed toward less aggressive treatments. This
new objective became important after a change in paradigms in
cancer treatment was proposed to the medical community in the
1970s. The change referred to the substitution of the traditional
paradigm of “maximum tolerable treatment” to the new opposite
paradigm of “minimum effective treatment.” Since the 1970s the
paradigm has been applied to many instances and the evolution
of treatment of breast cancer is an excellent model. The review of
this model is the aim of this paper.
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Randomized trials have contributed significantly to practice
changing in surgical oncology in the last 50 years. In the field of
breast surgery, the conduction of randomized trials was proven to
be vital for all the revolutionary changes performed. The passage
from “maximally tolerated” to “minimally effective” treatment
has not been easy and the idea of conserving a large portion
of an already affected organ was challenged by many surgical
oncologists. It was only the large randomized trials performed
in breast cancer patients that made possible the acceptance of
breast conservation, and led to a complete modification of the
principles of breast surgery. Over the years, Halsted mastectomy
was replaced by lumpectomy or quadrantectomy, and exter-
nal high energy radiotherapy was an integrated component of
treatment. An attempt to improve the prognosis through more
extended treatments was the aim of the trial on internal mam-
mary node dissection. A large randomized trial was published
in 1976 and it was an international trial comparing radical mas-
tectomy with and without internal mammary dissection (Lacour
et al., 1976). From 1963 to 1968, 1453 patients in 5 breast
centers were randomized. The 5 years survival was similar in
the two groups and only patients with medially located tumors
and positive axillary nodes were shown to moderately bene-
fit from internal mammary dissection. The Cancer Institute of
Milan participated in this study and published the 10-years fol-
low up of 716 patients in 1981 (Veronesi and Valagussa, 1981).
Overall survival (OS) and disease free survival were equal in
the two groups. There was no difference in recurrence rates
on the operating field, the axilla and the supraclavicular fossa.
The radical mastectomy group had higher parasternal recur-
rences compared to the group with the extended operation,
which; however, were relatively low (3.7%). The 10-years update
of the multicenter study that was published 2 years later con-
firmed no difference in survival and in relapse-free survival
(Lacour et al., 1983). This first trial attempted to explore the
impact of more aggressive surgery than the standard and failed
the goal.
Thereafter, the trend went to the opposite direction, to com-
pare radicalmastectomy with lessmutilating interventions, and to
investigate the role of radiotherapy in the local control. TheMilan
I trial (1973–1980) randomized 701 pT1 breast cancer patients
into either Halsted mastectomy or quadrantectomy with axillary
dissection and breast radiotherapy. The first results were pub-
lished in 1981 and showed no difference in disease-free (DFS) and
OS (Veronesi et al., 1981). The study update with a 20-years follow
up confirmed the preliminary findings, establishing the concept
of breast conservation as a standard of care (Veronesi et al., 2002).
In the same period in France, 179 patients were randomized to
either modified radical mastectomy or tumorectomy with axil-
lary sampling and breast irradiation (Sarrazin et al., 1989). Both
groups were shown to have similar OS, DFS, and LRR at 10 and
15 years (Arriagada et al., 1996).
In 1974, another randomized trial begun in the United States,
the NSABP B-04, that recruited 1079 breast cancer patients. In
case of clinically negative axilla, they were randomized to either
total mastectomy, with axillary radiotherapy or to total mastec-
tomy with delayed axillary dissection, in case of appearance of
clinically positive axillary nodes. Patients with clinically positive
nodes were randomized to either radical mastectomy or total
mastectomy with axillary radiotherapy. No benefit in OS and
DFS survival was found from radical mastectomy on the 10-years
update (Fisher et al., 1985b).
In 1976, the NSABP B-06 trial started randomizing patients to
total mastectomy, lumpectomy alone or lumpectomy with breast
radiotherapy (Fisher et al., 1985a, 1989, 2002). Based on the
accrual of 1851 patients, OS and distant DFS were similar between
the three groups, but radiotherapy was shown to reduce the breast
recurrence rate after lumpectomy.
Four years later, in 1979, the National Cancer Institute con-
ducted a prospective randomized study comparing modified
radical mastectomy vs. lumpectomy—with positive or negative
resection margins- with axillary dissection and adjuvant radio-
therapy (Lichter et al., 1992). After 20 years of follow up of
237 patients, OS and DFS were comparable, however, according
to the authors “long-term in-breast failures continued to occur
throughout the follow up” (Poggi et al., 2003).
A study with a similar design was launched in 1980 by the
EORTC. The 10801 trial randomized 868 patients with T1 and
T2 tumors until 1986 to either modified mastectomy or lumpec-
tomy –with positive or negative resection margins- with axillary
dissection and adjuvant radiotherapy (van Dongen et al., 2000).
At 10 years, the results were similar to those of the NCI trial. OS
and distant metastasis-free survival were similar; however, local
recurrences were statistically higher in the lumpectomy group.
Between 1983 and 1989 the Danish Breast Cancer Cooperative
Group after randomizing 905 patients to either modified radical
mastectomy or lumpectomy with axillary dissection and radio-
therapy, concluded that OS and DFS did not differ significantly
(Blichert-Toft et al., 1992).
These large randomized trials conducted in the 1970s and
early 1980s showed the way to “less surgery” and practically
changed the route of breast cancer surgery. Furthermore, they
confirmed the hypothesis that the prognosis of breast cancer
patients is linked to the presence or absence of distant metasta-
sis and changes in local treatment do not affect the OS. Breast
conservation became not only a viable option, but a standard
treatment, and those trials updates published in the beginning
of the twenty-first century confirmed that mutilating interven-
tions such as radical mastectomy belong to the past. However,
some uncertainty remained about the extent of the breast con-
servation. This issue was further investigated with a randomized
study (Milan II) that was conducted between 1985 and 1987 and
its results were published in 1990 (Veronesi et al., 1990). Seven
hundred and five patients with tumors up to 2.5 cm were ran-
domized to receive either quadrantectomy or lumpectomy. All
patients underwent axillary dissection and radiotherapy. In quad-
rantectomy, 2–3 cm of normal tissue surrounding the tumor was
excised, as well as the tumor overlying skin and the underly-
ing fascia. In lumpectomy, only a rim of 1 cm around the tumor
was excised. After a follow up of 10 years OS and distant metas-
tasis rate were not different, while in breast tumor recurrence
was significantly higher in the lumpectomy group (Mariani et al.,
1998).
Following the establishment of breast conservation as treat-
ment of choice for early breast cancer, the role of radiotherapy
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on loco-regional control remained to be clarified. Light was shed
on the effect of adjuvant radiotherapy by two randomized trials.
The first was conducted at the Milan Cancer Institute (Milan III)
between 1987 and 1989 and recruited 567 patients with tumors
up to 2.5 cm (Veronesi et al., 1993). They were randomized to
quadrantectomy with axillary dissection with or without adju-
vant radiotherapy. The radiotherapy group had a significantly
lower local recurrence rate; however, the 5-years OS was compa-
rable. Similarly, the Uppsala-Orbero Breast Cancer Study Group,
reported the same conclusions in a study of 381 patients with
pT1 tumors (Uppsala-Orebro Breast Cancer Study Group, 1990).
Radiotherapy is nowadays considered a component of breast con-
servation, at least in women who are younger than 60 years old.
For patients over 60 years old, a multicenter prospective ran-
domized trial was conducted, in order to assess the necessity of
radiotherapy. Between 2001 and 2005, 749 patients with early
breast cancer were assigned to either surgery only or to surgery
and breast radiotherapy and after 5 years of follow up there was
found a difference in in breast recurrence (2.5% vs. 0.7%), but no
difference in OS and in distant disease free survival (Tinterri et al.,
2009).
CONSERVATION OF AXILLARY NODES
The concept of “less surgery” was extended to the treatment of
the axilla. The role of radiotherapy on the axilla was evaluated in a
study conducted inMilan between 1995 and 1998 (Veronesi et al.,
2005). Four hundred and thirty five patients with small tumors
were randomized to either axillary radiotherapy or nothing. After
63 months of follow up, the axillary metastases presented were
lower than expected in both groups, suggesting that axillary dis-
section can be avoided in this subgroup of patients and that
radiotherapy has a protective effect.
The introduction of the sentinel lymph node biopsy put fur-
ther under investigation the role of axillary dissection. It was
already anticipated that the positivity of the axilla was an element
of prognosis and not a reason to perform more extensive surgery.
Sentinel lymph node biopsy is a method of “predicting” the axil-
lary status sparing the patient from axillary dissection and its
often devastating complications, like arm lymphedema. As soon
as the technique of sentinel lymph node biopsy was standard-
ized, a series of randomized control studies started worldwide.
The first was the Milan Trial, that in 1998 and 1999 randomized
506 patients with tumors up to 2 cm to two arms, one receiving
immediate axillary dissection and the other receiving the dissec-
tion only if the sentinel node was involved (Veronesi et al., 2006).
After 79 months of follow up, OS and DFS were equal. Only one
case of axillary recurrence was observed among the patients in the
SLN group who did not receive axillary dissection, although eight
false negatives would be expected. The long term analysis showed
that patients had less mortality rates after sentinel lymph node
biopsy policy than after immediate dissection (25 vs. 18 deaths).
An identical study was conducted between 1999 and 2004,
that randomized 5611 women with invasive breast cancer up to
4 cm from 80 centers in the USA and in Canada to either axillary
dissection or to sentinel lymph node biopsy alone with axil-
lary dissection only if the SLN was positive (Krag et al., 2010).
After 95.6 months of follow up, OS and DFS were similar in
the two groups. A sub-study reported that up to 12 months
postoperatively, patients with axillary dissection had significantly
higher arm morbidity and significantly more restricted work and
social activity and impaired QoL (Land et al., 2010).
The ALMANAC trial, is a multicenter UK trial, that studied
the QoL in patients with SLN vs. axillary dissection between 1999
and 2003 (Mansel et al., 2006). One thousand and thirty one
patients participated and at 12 months it was evident that lym-
phedema and sensory loss were higher in the axillary dissection
group; operative time, drainage use, hospitalization, and resump-
tion of normal life was much longer in axillary dissection group,
while in SLN group, patients had a higher QoL and arm function-
ing scores. The results of the SNAC trial and the Danish Breast
Cancer Cooperative Group confirmed the ones of ALMANAC
(Gill et al., 2009). Arm lymphedema and dysfunction were sig-
nificantly higher in the axillary dissection group at 12 months for
ALMANAC and at 18 months for DBCCG (Husted Madsen et al.,
2008).
The outcomes of these studies made clear that in case of non-
metastatic disease to the axilla, axillary dissection is not only
unnecessary, but also harmful. But what if the axillary lymph
nodes are positive? Is axillary dissection still necessary or can
it be avoided? The answer to this question, that takes conser-
vative treatment of breast cancer one step forward, is nowadays
under investigation. The NSABP Z0011 trial has randomized 891
patients with T1 and T2 tumors and positive SLN from 115 cen-
ters from 1999 to 2004 to receive axillary dissection or no further
treatment (Giuliano et al., 2011). At 6.3 years of follow up, the
5 years OS and the DFS were not different in the two groups,
suggesting that in this subgroup of patients, axillary dissection
may not be necessary. The EORTC 10981 AMAROS trial has
randomized patients with positive SLN to either axillary dissec-
tion or axillary radiotherapy from 2001 until 2010 and its results
are still to be published (Rutgers et al., 2004). Another multi-
centric randomized trial studying the role of axillary treatment
is the SOUND trial that started at the beginning of this year
at the IEO, in Milan. Patients with pT1 tumors and negative
axillary US scan are randomized to both SLN biopsy and axil-
lary dissection if positive or to no sentinel biopsy at all. The
results of this trial are awaited, as it might completely change
the approach to the axillary treatment, abandoning the sentinel
node biopsy in patients with an uninvolved axilla at clinical and
ultrasonographical examination.
BREAST RADIOTHERAPY
Adjuvant radiotherapy was shown to be an important element to
breast conservation. Breast radiotherapy has followed the same
course as breast surgery from large fields and high doses to
fields and doses as limited as possible. Recently, the concept of
accelerated partial breast irradiation has emerged and positive
experience is being accumulated. An interesting modality was
to anticipate the radiotherapy, which could be delivered during
surgery, intraoperative radiotherapy (IORT). Two large random-
ized IORT trials are ongoing at the moment, the ELIOT trial and
the TARGIT trial. In ELIOT protocol electrons are delivered in the
quadrantectomy site, while in the TARGIT protocol low energy X
rays are used in the lumpectomy site after the tumor resection
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and while the patient is still under general anesthesia. The first
results of ELIOT protocol show that pulmonary fibrosis is signifi-
cantly less in IORT patients compared with external radiotherapy
patients (Rampinelli et al., 2011). The TARGIT trial results show
that of 1113 patients who were randomized to either IORT or
external beam radiation, at 4 years of follow up 6/996 in the IORT
group and 5/1025 in the external radiotherapy group developed a
local recurrence (Vaidya et al., 2010). Complications and major
toxicity was similar in the two groups, while radiation toxicity
was significantly lower for IORT. The TARGIT trial outcomes are
encouraging and, if long term follow up, along with ELIOT trial
results, confirms the non-inferiority of IORT, it will be another
step in the evolution of breast cancer treatment.
CONSERVATIVE MASTECTOMY
Conservative mastectomy is the last step in breast cancer conser-
vative treatment. It combines total excision of breast parenchyma
sparing the skin and the nipple areola complex, thus offering
a very good aesthetic result by preserving the patient’s body
image thanks to the immediate reconstruction of the breast.
Randomized controlled trials are not available on this emerg-
ing technique, and so far the only available data in the literature
comes from cohort series with heterogeneity on indications and
reconstructive techniques. The outcomes on oncologic safety
are satisfactory, as is the cosmesis, according to surgeons’ and
patients’ evaluation. In our Institute, the European Institute of
Oncology, we have the largest series of patients treated with con-
servative mastectomy with OS rates similar to those of skin spar-
ing mastectomy and with superior aesthetic outcomes (Petit et al.,
2009). At the moment we are considering a randomized trial on
patients treated with conservative mastectomy focusing on IORT
on the conserved nipple areola complex, in order to evaluate the
sterilizing effect of radiotherapy on nipple recurrence.
CONCLUSIONS
The large number of randomized trials conducted in the last 50
years has completely overturned the radio-surgical breast can-
cer management. The long term beneficial effects were evident
especially with regards to the motivation of women to early
detection. Women know that the early discovery of a “small nod-
ule” on the breast will not only save their life, but will make
it possible to preserve their body image. In the western world,
most women participate in many large randomized programs
for early detection of breast cancer and the evolution of images
(mammography, ultrasound, andMRI) has greatly facilitated this
progress.
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